Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

2011154 citationsJournal Articlebronze Open Access

Authors

Miguel Nogué · Hospital Universitari de Vic

Antonieta Salud · Hospital Arnau de Vilanova

Pilar Vicente · Hospital General de Granollers

A. Arriví · Hospital Son Llatzer

José María Roca · University Hospital Mútua de Terrassa

Ferrán Losa · Ajuntament de L’Hospitalet

José Ponce

Abstract

Addition of bevacizumab to induction chemotherapy and chemoradiotherapy is feasible, with impressive activity and manageable toxicity. However, caution is recommended regarding surgical complications.

Topics & Keywords

Colorectal Cancer Surgical Treatments Colorectal Cancer Treatments and Studies Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 16, Issue 5, pp. 614-620

DOI: 10.1634/theoncologist.2010-0285

Field-Weighted Citation Impact: 4.16